Background: Acute myeloid leukemia is a complex and heterogeneous hematopoietic tissue neoplasm caused by gene mutations, chromosomal rearrangements and deregulation of gene expression. Some recent studies considered CD200 as a marker of bad prognosis in AML as it is linked to worse overall survival. The present study aimed to assess CD200 expression frequency in patients with AML and evaluate its association with different clinical and laboratory data.
Subjects & Methods: The study was carried on 28 newly diagnosed AML patients and 10 healthy subjects who served as a control group. All patients were subjected to routine laboratory investigations and measurement of CD200 level by flowcytometry.
Results: The 28 de novo AML patients were 15 males and 13 females with age ranging from 32 to 60 years with a mean±SD 48.32±7.88 years, and 10 healthy subjects who served as a control group with age ranged from 24 to 58 years with a mean ± SD 39.20±12.30 years. Cases were classified into CD200 positive (27 cases) and CD200 negative (1 case). Then Positive CD200 cases were classified into CD200 High expression and CD200 Low; patients with CD200